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EDITORIAL REVIEW
Pathophysiology of experimental nonoliguric acute renal failure
Acute renal failure (ARF), usually referred to as acute tubular
necrosis, can be defined as an abrupt and sustained decline in
glomerular filtration with resultant azotemia, caused by acute
ischemic and/or toxic insults. It is not immediately reversible
when causes are eliminated. This definition excludes prerenal
failure, immediately reversed by improving renal perfusion,
postrenal failure due to urinary tract obstruction and azotemia
caused by primary renal parenchymal inflammation. Some of
patients with ARF have oliguria (defined as a daily urine output
less than 400 ml) but others not. ARF patients who have urine
output more than 600 mllday are classified as nonoliguric.
Although the nonoliguric form of ARF was recognized more
than forty years ago [1, 2], it was not until the latter 1960s that
substantial numbers of patients with nonoliguric ARF were
encountered [3—10]. In recent years, the incidence of nonoligu-
nc ARF ranges from approximately 20 to more than 60% of all
ARF patients [11—16].
Since the reports of Baek, Makabali and Shoemaker [5] in
1975 and Anderson et al [7] in 1977, numerous clinical obser-
vations [8, 10, 11, 13, 15, 16] have shown nonoliguric ARF to
cause less morbidity and mortality than oliguric ARF. Oliguric
and nonoliguric ARF have similar etiologies. Little is known,
however, as to what determines oliguric or nonoliguric ARF.
Over the past two decades, efforts have been made to explore
the mechanisms for oliguric ARF, but much less attention was
directed to nonoliguric renal failure.
This review is focused on the pathophysiology of nonoliguric
acute tubular necrosis in the hope that it might stimulate further
advance in this area.
Clinical observations
There are numerous causes for nonoliguric ARF in humans.
Etiological factors commonly encountered in nonoliguric ARF
include surgical operations, trauma, burns, obstetric disorders,
rhabdomyolysis, septicemia, anesthetic agents, antineoplastic
drugs and antibiotics [3, 7, 9—12, 14, 16—22]. Most of these
factors also cause oliguric ARF. However, nephrotoxin-medi-
ated renal failure is more frequent in nonoliguric ARF [7]. In
particular, methoxyflurane [17], aminoglycosides [18] and cis-
platin (cis-diamminedichiorplatinum) [19] most often cause
nonoliguric or polyuric ARF at therapeutic doses. Nonoliguric
ARF following extensive burns and open heart surgery has been
frequently reported [3, 12, 20, 21]. Diuretics such as mannitol
and furosemide occasionally convert oliguric to nonoliguric
ARF [6, 23].
A number of clinical observations indicate that maximum
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blood urea nitrogen, serum creatinine and/or a daily increase in
serum creatinine are lower in nonoliguric ARF patients than in
oliguric patients [7, 16]. The urine sodium concentration and
fractional sodium excretion (FENa) are lower and urine to
plasma urea nitrogen ratios higher in nonoliguric ARF patients
[3, 7, 12, 15] (Table I), indicating possibly less severe tubular
injury. Of great interest, Myers et a! [21, 24] noted that
fractional clearances of smaller uncharged dextrans (Einstein-
Stokes radius <30 A) relative to inulin (radius 14 A) frequently
exceed unity in patients with nonoliguric ARF following cardiac
surgery. The finding suggests a size-dependent back-leakage of
glomerular filtrate in nonoliguric ARF patients, since inulin and
smaller uncharged dextrans are freely filtered at the glomerulus
and neither compound is reabsorbed from or secreted into
tubular fluid. Urine to plasma osmolality ratios (U/P0sm) exceed
unity in nonoliguric ARF following burns [12], but not 1.2 in a
series of patients with nonoliguric acute tubular necrosis [25].
Complications such as infections, gastrointestinal bleeding,
cardiac and respiratory failure, metabolic acidemia and neuro-
logical abnormalities often occur in ARF and aggravate the
clinical course. Nonoliguric ARF patients have fewer compli-
cations [7, 15], require dialysis less frequently [7, 11] and show
lower mortality than oliguric ARF patients [4-8, 13, 15].
These clinical observations suggest less severe renal injury in
nonoliguric ARF patients than in oliguric patients.
Animal studies
Nonoliguric ARF models
Experimental nonoliguric ARF can be produced by variously
modifying oliguric ARF-producing procedures. Oliguric ARF
models are classified into ischemic, nephrotoxic and myohemo-
globinuric ARF. To induce ischemic ARF, mechanical clamp-
ing of the renal artery or intrarenal infusion of norepinephrine
has been widely used. Oliguric nephrotoxic ARF can be pro-
duced by the intravenous or subcutaneous injection of higher
doses of nephrotoxic substances such as uranyl nitrate and
mercuric chloride. Oliguric myohemoglobinuric ARF has been
induced by the intravenous injection of methemoglobin or
myoglobin along with additional procedures such as dehydra-
tion and metabolic acidosis, or by the intramuscular or subcu-
taneous injection of hypertonic glycerol solution. Although
these animal models are not completely comparable to ARF in
humans, studies using them have advanced our knowledge of
oliguric ARF.
Numerous studies indicate that nonoligunc ARF can be
produced by modification of oliguric ARF-producing proce-
dures, such as shorter exposure to renal ischemia [26, 271,
smaller doses of nephrotoxic agents [28, 29], enhanced resis-
tance to an ARF insult in the host [30], saline loading [3 1—33],
diuretics [23, 34], anesthesia [35] and unilateral nephrectomy
[27, 36—38] (Table 2). Common drugs such as aminoglycosides
[39—42] and cisplatin [42—44] most often cause polyuric ARF in
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Table 1. Urinary diagnostic indices in ARF
Oliguric Nonoliguric References
Uosm, mOsm/kg H20 369 22
(N, 24)
343 17
(N, 31)
7
U/Per 16.5 3.0
(N, 24)
17.2 2.1
(N, 31)
7
U/Purea 3.3 0.5
(N, 24)
patients (N, 11)
7.4 1.1
(N, 31)
patients (N, 9)
7
UNa, mEqlliter >20 in 8
68±6
(N, 24)
<20 in 8
50±5
(N, 31)
58±9.1
(N, 16)
3 (burned
patients)
7
8
FENa, % 6.8 1.4
(N, 24)
12.8 1.8
(N, 80)
3.1 0.5
(N, 31)
10.5 3.8
(N, 23)
7
15
Abbreviations are: ARF, acute renal failure; Usm, urine osmolality;
U/Pcr, urine/plasma ratio of creatinine; U/Purea, urine/plasma ratio of
urea nitrogen; UNa, urine sodium concentration; FENa, fractional
excretion of sodium; N, number of cases.
Table 2. Nonoliguric ARF models
Model Animal
Nonoliguric ARF-
producing procedures References
Ischemic rat
rat
rat, dog
shorter exposure to
ischemia
anesthetic agents
unilateral nephrectomy
26, 27
35
27, 36—38
Nephrotoxic
Uranium rabbit
rabbit
smaller doses of the
agent
acquired insensitivity to
the agent
28
30
HgCI2 rat smaller doses of the 29
Potassium
rat
rat
agent
saline loading
nonoliguric
33
29, 45
dichromate
Gentamicin rat nonoliguric 39—42
Cisplatin rat nonoliguric 43, 44
Myohemoglobinuric
Myoglobin rat volume replacement 31
Glycerol rat volume replacement 32
humans and animals. Potassium dichromate [29, 45], sodium
chromate [46] and bis metabolite of the flame retardant tris
(2,3-dibromopropyl) phosphate [47] induce nonoliguric ARF in
rats.
Pat hophysiology
Prior to the discussion on the pathogenesis of nonoliguric
ARF, we summarize the pathophysiology of oliguric renal
failure (Table 3). The common pathogenetic pathway for isch-
emic and nephrotoxic ARF is renal cell injury. Renal ischemia
and nephrotoxins cause cellular injury by interfering with
cellular and subcellular plasma membrane transport [48]. The
mechanism for this probably differs according to causes. Acute
and progressive cellular injury induces the following changes at
the nephron level, leading finally to renal failure: (1) primary
decline in glomerular filtration due to decreased renal blood
Table 3. Pathogenetic factors operative in experimental ARF
Model
Decreased
RBF
Decreased
K
Tubular
obstruction
Back-leakage of
filtrate
Ischemic + ? ++ ++
Uranium — ++ ? ++
HgCI2 — probably + + + +
Gentamicin + + + probably + —(+ at higher doses)
Cisplatin + ? +
Glycerol ++ + —
Abbreviations are: ARF, acute renal failure; RBF, renal blood flow;
K, glomerular capillary ultrafiltration coefficient; + +, major pathoge-
netic factor; +, mechanism may be operative; —, mechanism is not a
prerequisite for ARF; ?, mechanism is not evaluated adequately.
flow (RBF) and/or reduced glomerular capillary ultrafiltration
coefficient (Kf, hydraulic conductivity multiplied by filtering
surface area); (2) tubular obstruction by casts and cellular
debris; and (3) back-leakage of glomerular filtrate across dam-
aged tubular epithelia [49, 50]. Mediators of reduced RBF in
ARF remain controversial, but suggested factors include in-
creased adrenergic activity, altered vascular reactivity, renin-
angiotensin stimulation, tubuloglomerular feedback, elevated
plasma level of vasopressin, enhanced synthesis of thrombox-
ane, adenosine and endothelin, endothelial cell swelling in
kidney vessels, and intravascular coagulation [49—51]. Numer-
ous studies indicate that the roles of these pathogenetic factors
in ARF differ with different models and at different stages
(Table 3).
Major pathophysiologic events during the initiation and main-
tenance stages of ischemic ARF appear to be tubular obstruc-
tion and transtubular back-leakage of filtrate [49, 50]. Reduction
in RBF contributes to the initial fall in the glomerular filtration
rate (GFR) but may be insufficient to diminish GFR. Recent
studies [51—53] suggest medullary hypoperfusion or vascular
congestion as the pathogenetic event leading to reduction in
RBF and GFR. Kf has not been directly evaluated in the
ischemic model.
In uranium-induced ARF, reduced K1 and enhanced back-
leakage of filtrate are widely accepted as major pathogenetic
factors [49, 50]. Decreased RBF is not always a prerequisite for
producing and maintaining ARF. The role of tubular obstruc-
tion remains unclarified.
As with uranium-induced ARF, early reduction in RBF does
not appear to cause a progressive fall in GFR in mercuric
chloride-induced ARF [49, 50]. Reduction in K1 probably oc-
curs. Tubular obstruction may be a contributory factor causing
GFR decline at the maintenance stage of ARF. Enhanced
back-leakage of filtrate also contributes to a decline in whole
kidney GFR.
Reduction in RBF appears to be a decisive factor for the
initial fall in GFR but not at the maintenance stage of glycerol-
induced ARF [49, 50, 54]. Whether changes in K1 contribute to
a decline in GFR is unknown. Tubular obstruction may be
important to the maintenance of ARF. Back-leakage of tubular
fluid accounts for only a small portion of the decline in whole
kidney GFR in the glycerol model.
It remains unclear whether the same pathogenetic factors as
those in oliguric ARF are operative in nonoliguric ARF or
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additional unique factors contribute to this condition. To ex-
plain the initiation of ARF, the tubuloglomerular feedback
hypothesis has been invoked by Thurau's group [55]. Ischemic
and toxic cell injury affects transport activity at proximal
tubules, thereby increasing the sodium chloride concentration
in tubular fluid arriving at the macula densa. This increase in
sodium chloride stimulates the renin-angiotensin system in the
juxtaglomerular apparatus. Enhanced production of angiotensin
II reduces glomerular filtration and hence urine flow through
afferent arteriolar constriction and probably mesangial cell
contraction. In the presence of uncontrolled glomerular filtra-
tion due to altered tubuloglomerular feedback, however, re-
duced tubular reabsorptive capacity results in high urine flow
[55]. Controversy still exists regarding the roles of tubuloglom-
erular feedback in renal circulatory regulation and the patho-
genesis of ARF [56, 57]. Klotman and Yarger [57] have dem-
onstrated that RBF decreases but GFR does not change in the
early phase of gentamicin-induced ARF in rats, despite reduced
chloride concentration in the early distal tubule.
Finn [35] noted that polyuric ischemic ARF kidneys are
composed of a heterogeneous population of nephrons but
oliguric kidneys are homogeneous in appearance, and stressed
the importance of nephron heterogeneity in the pathogenesis of
nonoliguric ARF. Gordon and Schrier [58] suggested that
suppressed tubular reabsorption of sodium, impaired water
transport and conservation, and heterogeneous nephron injury
are important pathogenetic factors of nonoliguric ARF. Also,
our and other studies indicate that whatever nonoliguric ARF-
producing procedure, renal morphologic and functional damage
is less severe in the nonoliguric form than in the oliguric form of
renal failure, as discussed in the following.
Shorter exposure to renal ischemia
Shorter duration of the exposure to renal ischemia may cause
nonoliguric ARF. A number of investigations showed that renal
ischemia due to renal artery clamping [26, 59, 60] or intrarenal
norepinephrine infusion [27, 61] causes either oliguric or non-
oliguric ARF in rats and dogs, depending on duration of the
exposure to ischemia. Furthermore, Donohoe et al [26] have
demonstrated that a longer duration of renal artery clamping
causes more extensive proximal tubular necrosis, more pro-
nounced tubular obstruction due to swollen blebs of brush
border lost from tubular epithelium and greater back-leakage of
filtrate. In the norepinephrine model, recovery of RBF and
GFR is more significantly delayed with longer duration of
infusion [27]. Therefore, nonoliguric ischemic ARF appears to
be associated with less severe renal morphologic and functional
injury.
Smaller doses of nephrotoxic agents
Nephrotoxic agents may induce either oliguric or nonoliguric
ARF, depending on doses of agents. Indeed, higher doses of
heavy metals such as uranium [28, 62, 63] and mercuric chloride
[29, 33, 64, 65] induce oliguric ARF in rats and rabbits but
smaller doses result in nonoliguria. In these nephrotoxic mod-
els, nonoliguria appears to be closely related to less severe renal
injury. For example, in uranium-induced ARF, decrease in
GFR and increase in serum creatinine are significantly less in
the nonoliguric form than in the oliguric form [28, 63]. In either
case, RBF is maintained at or above the normal level with or
without the initial moderate reduction [28, 62, 63]. Kf decreases
in a dose-dependent fashion in uranium-induced ARF rats [63].
Morphologic tubular injury is less severe in the nonoliguric
form than in the oliguric form of ARF [28]. Intratubular inulin
microinjection [63, 66] and retrograde intraureteral inulin infu-
sion experiments [28] have shown a dose-related back-leakage
of tubular fluid in uranium-induced ARF rats and rabbits, with
higher doses causing greater leakage. Also, in the mercuric
chloride model, the magnitude of back-leakage appears to be
related to the dosage of the agent [65—67]. Although FENa
increases along with reduction in U/P0sm and papillary osmolal
concentration in oliguric and nonoliguric ARF [28, 62], it is
unclear whether these tubular defects are less severe in the
nonoliguric form. Polyuria, decline in GFR, tubular obstruc-
tion, back-leakage of filtrate and renal concentrating defect
occur in potassium dichromate (15 mg/kg)-induced ARF rats as
well [29, 45]. However, whether higher doses of this agent
cause oliguric ARF with more severe renal injury is unknown.
Common drugs such as aminoglycosides [40, 42, 68, 69] and
cisplatin [43, 44] most often induce a renal concentrating defect
and polyuric ARF in rats. It is noteworthy that an increase in
urine output precedes a decline in GFR in gentamicin-mediated
ARF [40, 42, 68]. This tubular defect is not always accompanied
by enhanced urinary solute excretion, increased FENa or re-
duced tubular reabsorption of solute free water [40, 69], but is
resistant or partially responsive to exogenous antidiuretic hor-
mone [68]. Enhanced urine flow probably attenuates intratubu-
lar cast formation and enhances urinary excretion of gentami-
cm. Although the principal mechanism for gentamicin-mediated
ARF is thought to be a primary decline in GFR due to reduced
Kf [70], decreased glomerular plasma flow [70, 71] and tubular
obstruction [691 also contribute to the decline in GFR at a dose
of 40 mg/kg/day or more. Back-leakage of filtrate occurs at 100
or 150 mg/kg/day [41] but not at 4 to 40 mg/kg/day in rats [70],
indicating possibly a dose-related leakage. At a dose of 5 or 10
mg/kg of cisplatin, polyuria [43, 44], reduction in RBF [72] and
single nephron GFR [43, 44], back-leakage of filtrate [44] and
probably tubular obstruction [44] occur in rats. These data
suggest that the same pathogenetic factors as those in oliguric
ARF operate to a less extent in nonoligunc nephrotoxic ARF.
Volume replacement
An ARF insult often induces oliguric ARF in dehydrated
animals but nonoliguric renal failure in the well-hydrated state
[3 1—33, 73]. For example, an intravenous infusion of myoglobin
or intramuscular injection of hypertonic glycerol solution in-
duces oliguric ARF in dehydrated rats but nonoliguric renal
failure in well-hydrated animals [31, 32], with less decline in
GFR in nonoliguric ARF [31]. In the oliguric form of glycerol-
induced ARF, RBF reduces through plasma volume contraction
[54], decreased cardiac output [74] and renal vasoconstriction
[54]. Dehydration and concentrated acidic urine probably po-
tentiate nephrotoxic effects of myoglobin and hemoglobin re-
leased by rhabdomyolysis and hemolysis, as both heme pig-
ments produce hematin [75] which is toxic to the kidney and
blood vessels [76, 77]. Furthermore, hematin precipitates in
concentrated acidic urine, thereby impairing renal function [78].
There is a possibility, therefore, that volume replacement
reduces severity of glycerol-induced ARF through improved
RBF and lessened intratubular cast formation. Reineck et al
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[79] and Cushner et a! [801 actually demonstrated in glycerol-
induced ARF rats that acute or chronic volume loading with
Ringer solution lessens the initial decline in GFR and cast
formation but not tubular necrosis.
Saline loading also attenuates a progressive fall in GFR in
uranium-induced ARF rats, without reducing severity of tubu-
lar necrosis [73]. This beneficial effect of saline loading appears
to be associated with lessened cast formation rather than with
suppressed renin-angiotensin activity or enhanced urinary ura-
nium excretion [73]. These data suggest that volume loading
with saline attenuates decline in GFR through lessened cast
formation and improved RBF in some ARF models.
Diuretics
Mannitol and/or loop diuretics also attenuate decline in GFR
without reducing severity of tubular necrosis, when adminis-
tered before ARF insults [23]. When given at the initiation or
maintenance stage, these agents occasionally convert oliguric
to nonoliguric ARF [23]. Mannitol is effective in preventing
ARF due to renal artery clamping [81, 82], norepinephrine [34,
83, 84] and mercuric chloride [81]. Furosemide has the protec-
tive effect against ARF caused by norepinephrine [34] or
smaller doses of mercuric chloride [85] but is ineffective or
rather deleterious in cephaloridine- [86] and glycerol-induced
ARF [87].
The protective effects of mannitol and furosemide are thought
to be mediated through lessened intratubular cast formation and
improved RBF [34, 83, 84]. Patak et al [34] noted that the
protective effects of these diuretics against norepinephrine-
induced ARF correlate with increased urinary solute excretion
rather than with improved RBF. Enhanced solute and water
excretion may facilitate flushing of intratubular casts. More-
over, hypertonic mannitol improves renal function through
amelioration in ischemia-induced vascular cell swelling and
outer medullary congestion [53]. Furosemide suppresses so-
dium reabsorption in the medullary thick ascending limb of the
Henle's loop. This tubular segment appears to be highly sus-
ceptible to hypoxic and toxic insults [51, 52]. Therefore, loop
diuretics may attenuate cell injury at this site through reduced
cell transport work [51, 52].
Whether the conversion of oliguric to nonoligunc ARF,
caused by diuretics, is associated with improved renal function
remains unclear. Eliahou and Bata [88] and Luke et al [89]
noted that tubular function is better in patients who respond to
mannitol with diuresis than in nonresponders. The presence of
some undamaged nephrons may be required for the conversion
to nonoliguria.
Enhanced resistance to ARF
Renal cell injury in ARF should be lessened by reduced renal
sensitivity to ischemia and/or nephrotoxins. A number of stud-
ies have demonstrated that prior ARF provides higher resis-
tance to a subsequent challenge with the same or different agent
[90]. Our previous study [30] showed that an intravenous
injection of 2 mg/kg of uranyl acetate usually induces oliguric
ARF in normal rabbits but nonoliguric ARF in animals previ-
ously administered 0.9 mg/kg of the agent. In this experiment,
we found that reduction in whole kidney GFR, increase in
serum creatinine and severity of tubular injury are less in
nonoliguric ARF rabbits than in oliguric animals, a finding
which suggests enhanced resistance to rechallenge injury in
animals recovering from uranium-mediated nephropathy.
Why are animals recovering from ARF highly resistant to
rechallenge injury? This acquired resistance to ARF appears to
be associated with high resistance of regenerated tubular epi-
thelial cells to a subsequent renal failure challenge [90—92], but
not with renal hemodynamic changes [30, 90, 93] or altered
renin-angiotensin activity [94]. Wilkes et al [95] demonstrated
that the glomerular contractile response to angiotensin II is
totally inhibited in rats recovering from glycerol-induced ARF,
and suggested that this glomerular refractoriness to angiotensin
contributes partially to increased resistance to a subsequent
renal failure challenge in this model. In ischemic and uranium
models in rabbits, however, glomerular refractoriness to vaso-
constrictor substances such as angiotensin, arginine vasopres-
sin and norepinephrine appears to be unrelated to increased
resistance to a second renal failure challenge [96—98]. High
resistance of regenerated tubular epithelial cells to rechallenge
injury would not be due to a smaller amount of a toxin bound to
regenerated cells, because the kidney with prior uranyl acetate-
mediated injury achieved similar tissue levels of uranyl cation
as the previously unchallenged kidney when subjected to the
second injection of the agent [98].
Accumulating evidence indicates that reactive oxygen metab-
olites are important mediators of ischemic and toxic renal cell
injury [99, 100]. Some investigators demonstrated the protec-
tive effects of antioxidant agents against ischemic, glycerol- and
gentamicin-induced ARF [99—103]. Yoshioka et a! [104] noted
that increased resistance to rechallenge injury in rats recovering
from ischemic ARF is closely related to enhanced antioxidant
enzyme activity in glomeruli. However, the activity of antiox-
idant enzymes such as superoxide dismutase, glutathione per-
oxidase and catalase does not increase in the rabbit kidney
recovering from uranium-mediated injury [105]. Furthermore,
the generation of hydrogen peroxide is enhanced in glycerol and
gentamicin models of ARF in rats but not in uranium and
endotoxin models [100, 106]. Taken together, these data suggest
that pathogenetic roles of antioxidant enzymes in acquired
resistance to ARF differ with different models.
Na ,K-ATPase is essential to cell volume regulation [107].
Uranyl nitrate inhibits the activity of Na,K-ATPase derived
from human and animal tissues [108]. Cronin et a! [109, 110]
noted that the protective effect of thyroid hormone against
nephrotoxicity of gentamicin and uranyl nitrate is associated
with enhanced Na,K-ATPase activity in the renal cortex. A
significant increase in this enzyme activity has been found in the
outer medulla of the rabbit kidney recovering from uranium-
mediated cell injury (note added in proof). It is unclear, how-
ever, whether enhanced Na ,K-ATPase activity is required
for increased resistance of regenerated tubular epithelial cells to
rechallenge injury or is only an epiphenomenon.
One of the other possibilities may be that increased resistance
of regenerated tubular epithelial cells is mediated through local
production of growth factor(s). There is evidence that local
production of growth factor(s) occurs following the initial
exposure to a nephrotoxin to facilitate recovery of injured cells
and stimulate mitogenesis to replace necrotic tubules [1111. A
second challenge with the toxin may more rapidly trigger the
synthesis and release of growth factor(s), thus accelerating
repair of the tubular lesion [111]. This brisk repair would be
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interpreted as enhanced resistance to a second renal failure
challenge. Exogenous epidermal growth factor actually accel-
erates recovery from ischemic and mercuric chloride-induced
ARF in rats [112—114]. It remains unclarified, however, whether
a second exposure to the toxin more rapidly triggers the
production and release of the growth factor(s).
Whatever the mechanism, animals recovering from ARF are
functionally and morphologically protected against a rechal-
lenge with the same or different agent. In these animals,
nonoliguric ARF occurs at higher doses of nephrotoxic agents,
sufficient to induce oliguric ARF in normal animals.
Anesthesia
The depth of anesthesia during renal artery clamping may
modify severity of ARF. Finn [35] has demonstrated that one
hour clamping of the renal artery induces polyuric ARF in rats
when anesthetized with 150 mg/kg of thiobarbiturate mactin,
while oliguric ARF occurs with 60 mg/kg of oxybarbiturate
sodium pentobarbital. In these ischemia models, he found that
inulin and para-aminohippurate clearances and urinary sodium
excretion are significantly higher in polyuric ARF than in
oliguric ARF. The mechanisms whereby a higher dose of
mactin attenuates ischemic renal injury are unknown. The
depth of anesthesia might be one factor [115].
What is more interesting is a significant difference in nephron
population between oliguric and nonoliguric ARF kidneys. Finn
[351 noted that the surface of the oliguric kidney is homoge-
neous in appearance, proximal convoluted tubules are uni-
formly dilated, tubular fluid flow is absent and intratubular
pressure high, while the polyuric kidney is composed of normal
tubules with spontaneous fluid flow and dilated tubules without
fluid flow. From these observations, Finn stressed the impor-
tance of nephron heterogeneity in the pathogenesis of nonolig-
uric ischemic ARF. Karlberg et al [116] and Neugarten, Ayned-
jian and Bank [69] also observed nephron heterogeneity in
polyuric ARF following renal artery clamping and gentamicin
administration, respectively. Polyuric ARF in some animal
models may be associated with heterogeneous nephron injury.
Unilateral nephrectomy
Antecedent unilateral nephrectomy attenuates ischemic renal
injury and/or facilitates recovery from renal dysfunction [27, 37,
38]. Fernandez-Repollet and Finn [37] and Fried et al [38] have
demonstrated that one hour clamping of the renal artery induces
polyuric ARF in previously uninephrectomized rats but that
oliguria occurs in the presence of the contralateral healthy
kidney. They found that the decline in inulin clearance at 2, 24
and 48 hours after the clamping is significantly less and tubular
cell injury less severe in the polyuric ARF kidney than in the
oliguric kidney. A renal concentrating defect due to diminished
papillary solutes occurs in both polyuric and oliguric kidneys
[36, 117].
Why does antecedent unilateral nephrectomy attenuate isch-
emic renal injury and/or enhance recovery from renal dysfunc-
tion? Fried et al [38] noted that there is no significant difference
in recovery of GFR in the postischemic kidney between rats
uninephrectomized at 14 days and immediately prior to renal
artery clamping, and suggested that the beneficial effect of
antecedent unilateral nephrectomy is not a consequence of
renal compensatory hypertrophy. A possibility cannot be corn-
pletely excluded, however, that the production of humoral
factor(s) [118], which stimulates renal compensatory growth, is
enhanced following uninephrectomy and accelerates repair of
injured cells. Fernandez-Repollet and Finn [37] demonstrated
that recovery of GFR following renal artery clamping is more
significantly facilitated in previously uninephrectomized rats
than in nonnephrectomized animals, and that vascular resis-
tance in the postischemic kidney increases above the preclamp-
ing level in nonnephrectomized rats but not in uninephrecto-
mized animals. They suggested that the effect of unilateral
nephrectomy is mediated through changes in preglomerular
vascular resistance. However, they did not identify the factors
responsible for changes in the vascular resistance.
Recent evidence [119] indicates that renal ischemia results in
increased endothelin concentration in the renal parenchyma
and that tissue ischemia potentiates vasoconstricting and toxic
effects of endothelin. Kon et al [120] noted remarkable amelio-
ration in single nephron GFR and glomerular plasma flow
caused by anti-endothelin serum infusion in the postischemic
rat kidney. Renal ischemia also enhances the local production
and release of angiotensin and thromboxane [121] but reduces
the synthesis of endotheliurn-derived relaxing factors [122]. Our
preliminary study showed that unilateral nephrectomy results in
increased plasma atrial natriuretic peptide concentration and
decreased thromboxane A2 content in the renal cortex in rats
(note added in proof). Following one hour of clamping the renal
artery, endothelin and thromboxane contents in the cortex
increase to a greater extent in nonnephrectomized rats than in
uninephrectornized animals. The plasma renin activity and
renin content in the postischemic kidney increase significantly
in nonnephrectomized rats but not in uninephrectornized ani-
mals. Therefore, the difference in hernodynarnic alterations in
the postischernic kidney between nonnephrectornized and uni-
nephrectomized rats might be attributed, at least in part, to the
difference in renal tissue contents of endothelin and other
vasoactive substances.
It is unclear whether unilateral nephrectomy lessens toxic
renal cell injury. Elliott et al [92] noted that antecedent unilat-
eral nephrectomy has no remarkable effect on renal sensitivity
to gentamicin but facilitates recovery from renal dysfunction in
rats. On the contrary, Thiel et al [123] showed that there is no
significant difference in severity of azotemia between mercuric
chloride-induced ARF in nonnephrectomized and uninephrec-
tomized rats.
Whatever the mechanism, unilateral nephrectomy lessens
ischemic renal injury and/or facilitates recovery from renal
dysfunction. Effects of uninephrectomy on nephrotoxic ARF
remain unclarified.
Metabolic aspects of nonoliguric ARF
Less information is available as to whether metabolic impair-
ment in the kidney is less severe in nonoliguric ARF than in
oliguric renal failure. Mohaupt and Kramer [124] noted that one
hour of clamping the renal artery following previous anesthesia
and surgical operation induces either oliguric or nonoliguric
ARF in rats, depending on the time interval between the initial
surgery and renal artery clamping. In these models, they found
that the ATP concentration and the rate of ATP synthesis in
mitochondria in the renal cortex are more significantly reduced
in the oliguric ARF kidney than in the nonoliguric kidney, while
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there is no significant difference in reduction in the medullary
Na ,K-ATPase activity between oliguric and nonoliguric kid-
neys.
Concluding remarks
As discussed above, renal ischemia and nephrotoxic agents
cause either oliguric or nonoliguric ARF, depending not only on
the duration of the exposure to isehemia or doses of toxins but
also on multiple predisposing and conditioning factors in the
host that govern sensitivity to an ischemic or toxic insult. Renal
cell injury due to an ischemic or toxic insult is significantly
attenuated by acquired insensitivity to the insult, unilateral
nephrectomy and probably deep anesthesia. Diuresis and solute
diuresis caused by saline loading and/or diuretics prevent or
attenuate decline in GFR through lessened intratubular cast
formation in some ARF models. Owing to a paucity of investi-
gation, however, little is known as to what mechanisms are
responsible for acquired insensitivity to an ARF insult and why
unilateral nephrectomy or deep anesthesia lessens ischemic
renal injury. Further investigations using newly-developed bi-
ological techniques should provide important information.
Whatever the cause, heterogeneous or less severe renal
morphologic and functional damage appears to be a common
feature in nonoliguric ARF. Numerous studies indicate that
many of the same pathogenetic factors as those in oliguric ARF,
such as reduction in RBF and Kf, tubular obstruction, back-
leakage of glomerular filtrate, suppressed tubular reabsorption
of sodium and water, operate to a less extent in nonoliguric
ARF. There is no evidence that additional unique factors
contribute to nonoliguric ARF. From these observations, we
suggest that in nonoliguric ARF, suppressed tubular reabsorp-
tion of sodium and water fully compensates for less reduction in
glomerular filtration and back-leakage of filtrate, so that urine
output is well maintained. In contrast, significantly reduced
glomerular filtration and enhanced back-leakage of filtrate can-
not be compensated for by suppressed tubular reabsorption, so
that oliguria ensues. To ascertain this view, further comparative
studies on oliguric and nonoliguric forms of ARF should be
conducted.
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